Skip to main content

United States Emergency Department Use of Medications with Pharmacogenetic Recommendations.

Publication ,  Journal Article
Limkakeng, AT; Manandhar, P; Erkanli, A; Eucker, SA; Root, A; Voora, D
Published in: West J Emerg Med
September 23, 2021

INTRODUCTION: Emergency departments (ED) use many medications with a range of therapeutic efficacy and potential significant side effects, and many medications have dosage adjustment recommendations based on the patient's specific genotype. How frequently medications with such pharmaco-genetic recommendations are used in United States (US) EDs has not been studied. METHODS: We conducted a cross-sectional analysis of the 2010-2015 National Hospital Ambulatory Medical Care Survey (NHAMCS). We reported the proportion of ED visits in which at least one medication with Clinical Pharmacogenetics Implementation Consortium (CPIC) recommendation of Level A or B evidence was ordered. Secondary comparisons included distributions and 95% confidence intervals of age, gender, race/ethnicity, ED disposition, geographical region, immediacy, and insurance status between all ED visits and those involving a CPIC medication. RESULTS: From 165,155 entries representing 805,726,000 US ED visits in the 2010-2015 NHAMCS, 148,243,000 ED visits (18.4%) led to orders of CPIC medications. The most common CPIC medication was tramadol (6.3%). Visits involving CPIC medications had higher proportions of patients who were female, had private insurance and self-pay, and were discharged from the ED. They also involved lower proportions of patients with Medicare and Medicaid. CONCLUSION: Almost one fifth of US ED visits involve a medication with a pharmacogenetic recommendation that may impact the efficacy and toxicity for individual patients. While direct application of genotyping is still in development, it is important for emergency care providers to understand and support this technology given its potential to improve individualized, patient-centered care.

Duke Scholars

Published In

West J Emerg Med

DOI

EISSN

1936-9018

Publication Date

September 23, 2021

Volume

22

Issue

6

Start / End Page

1347 / 1354

Location

United States

Related Subject Headings

  • United States
  • Pharmacogenetics
  • Medicare
  • Medicaid
  • Humans
  • Health Care Surveys
  • Female
  • Emergency Service, Hospital
  • Cross-Sectional Studies
  • Aged
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Limkakeng, A. T., Manandhar, P., Erkanli, A., Eucker, S. A., Root, A., & Voora, D. (2021). United States Emergency Department Use of Medications with Pharmacogenetic Recommendations. West J Emerg Med, 22(6), 1347–1354. https://doi.org/10.5811/westjem.2021.5.51248
Limkakeng, Alexander T., Pratik Manandhar, Alaatin Erkanli, Stephanie A. Eucker, Adam Root, and Deepak Voora. “United States Emergency Department Use of Medications with Pharmacogenetic Recommendations.West J Emerg Med 22, no. 6 (September 23, 2021): 1347–54. https://doi.org/10.5811/westjem.2021.5.51248.
Limkakeng AT, Manandhar P, Erkanli A, Eucker SA, Root A, Voora D. United States Emergency Department Use of Medications with Pharmacogenetic Recommendations. West J Emerg Med. 2021 Sep 23;22(6):1347–54.
Limkakeng, Alexander T., et al. “United States Emergency Department Use of Medications with Pharmacogenetic Recommendations.West J Emerg Med, vol. 22, no. 6, Sept. 2021, pp. 1347–54. Pubmed, doi:10.5811/westjem.2021.5.51248.
Limkakeng AT, Manandhar P, Erkanli A, Eucker SA, Root A, Voora D. United States Emergency Department Use of Medications with Pharmacogenetic Recommendations. West J Emerg Med. 2021 Sep 23;22(6):1347–1354.

Published In

West J Emerg Med

DOI

EISSN

1936-9018

Publication Date

September 23, 2021

Volume

22

Issue

6

Start / End Page

1347 / 1354

Location

United States

Related Subject Headings

  • United States
  • Pharmacogenetics
  • Medicare
  • Medicaid
  • Humans
  • Health Care Surveys
  • Female
  • Emergency Service, Hospital
  • Cross-Sectional Studies
  • Aged